A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin
Luke McLean, Tessa Altair Morris, Ann Gramza, Stephen V. Liu, Saad A. Khan, A. Dimitrios Colevas, Tillman Pearce, Danny Rischin
Topics & Concepts
MedicineInternal medicineHead and neck squamous-cell carcinomaHead and neck cancerOncologyProdrugHypoxia (environmental)CancerGastroenterologyPharmacologyOrganic chemistryChemistryOxygenCancer, Hypoxia, and MetabolismHead and Neck Cancer StudiesHER2/EGFR in Cancer Research